F. Hoffmann-la Roche Ag

Hoffmann-la Roche Inc.

Michael Lindemann

Christian Gossens

Christian Czech

Ignacio Fernandez Garcia

Joerg Sprengel

Timothy Kilchenmann

Florian Lipsmeier

Detlef Wolf

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Digital biomarker

Display screen with transitional graphical user interface

Growing community of inventors

Schopfheim, Germany

Michael Lindemann